StocksFundsScreenerSectorsWatchlists
EXAS

EXAS - Exact Sciences Corp Stock Price, Fair Value and News

61.59USD-1.89 (-2.98%)Delayed as of 19 Apr 2024, 10:45 am ET

Market Summary

EXAS
USD61.59-1.89
Delayedas of 19 Apr 2024, 10:45 am
-2.98%

EXAS Alerts

  • 1 major insider sales recently.

EXAS Stock Price

View Fullscreen

EXAS RSI Chart

EXAS Valuation

Market Cap

11.5B

Price/Earnings (Trailing)

-56.42

Price/Sales (Trailing)

4.61

EV/EBITDA

-59.86

Price/Free Cashflow

360.74

EXAS Price/Sales (Trailing)

EXAS Profitability

Operating Margin

73.83%

EBT Margin

-8.07%

Return on Equity

-6.49%

Return on Assets

-3.15%

Free Cashflow Yield

0.28%

EXAS Fundamentals

EXAS Revenue

Revenue (TTM)

2.5B

Rev. Growth (Yr)

16.98%

Rev. Growth (Qtr)

2.95%

EXAS Earnings

Earnings (TTM)

-204.1M

Earnings Growth (Yr)

61.04%

Earnings Growth (Qtr)

-6.4K%

Breaking Down EXAS Revenue

52 Week Range

61.30100.77
(Low)(High)

Last 7 days

-13.0%

Last 30 days

2.5%

Last 90 days

-3.6%

Trailing 12 Months

-7.6%

How does EXAS drawdown profile look like?

EXAS Financial Health

Current Ratio

2.32

Debt/Equity

0.49

Debt/Cashflow

0.1

EXAS Investor Care

Shares Dilution (1Y)

1.86%

Diluted EPS (TTM)

-1.14

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
20232.2B2.3B2.4B2.5B
20221.9B1.9B2.0B2.1B
20211.5B1.7B1.8B1.8B
20201.1B1.1B1.3B1.5B
2019526.2M623.2M723.7M876.3M
2018307.9M353.2M398.9M454.5M
2017132.9M169.4M213.8M266.0M
201650.0M63.1M78.6M99.4M
20155.8M13.9M26.5M39.4M
20143.4M2.4M1.3M1.8M
20134.1M4.1M4.1M4.1M
20124.2M4.2M4.2M4.1M
20115.1M4.8M4.5M4.2M
201005.0M5.1M5.3M
20090004.8M
GRUFITY'S FAIR VALUE MODEL

Stocks Marked 'Very Cheap' by Grufity's Fair Value Model Have Outperformed Russell 2000 Index

Small Caps and Mid Caps are mostly overlooked by investors as all the focus goes to Magnificent 7. These stocks that are not part of the beauty contest require a deeper look. However, all large cap stocks were once small caps. Grufity's Fair Value model opens up this unverse as it separates high-performing, rewarding stocks from low-performing risky stocks. <b>Russell 2000 stocks that were marked 'Very Cheap' by the model doubled in three years while the index was flat.</b>

PurpleZone


Returns of $10,000 invested in:

Very Cheap Stocks: $21,859
Russell 2000 Index: $10,334
Very Expensive Stocks: $8,224


Russell 2000 stocks considered 'Very Cheap' by the model greatly outperformed Russell 2000 index and the 'Very Expensive' bucket over past three years.

Russell 2000 Index
Very Expensive Stocks
Very Cheap Stocks
Try For Just $1.99

Tracking the Latest Insider Buys and Sells of Exact Sciences Corp

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Apr 02, 2024
baranick brian
sold
-73,393
79.43
-924
evp, gm., precision oncology
Apr 01, 2024
condella sarah
sold
-140,000
70.00
-2,000
evp, human resources
Mar 28, 2024
condella sarah
sold
-140,000
70.00
-2,000
evp, human resources
Mar 01, 2024
elliott jeffrey thomas
sold
-143,080
59.32
-2,412
chief financial officer
Mar 01, 2024
cunningham everett
sold
-143,080
59.32
-2,412
chief commercial officer
Mar 01, 2024
condella sarah
sold
-102,268
59.32
-1,724
evp, human resources
Mar 01, 2024
herriott james
sold
-51,133
59.32
-862
general counsel
Mar 01, 2024
conroy kevin t
sold
-490,636
59.32
-8,271
president and ceo
Mar 01, 2024
levangie daniel j
sold
-287,500
57.5
-5,000
-
Mar 01, 2024
orville jacob a
sold
-127,775
59.32
-2,154
general manager, screening

1–10 of 50

Which funds bought or sold EXAS recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
Apr 17, 2024
Stanley-Laman Group, Ltd.
reduced
-0.46
-624,644
8,196,730
1.15%
Apr 17, 2024
BARRETT & COMPANY, INC.
unchanged
-
-157
2,210
-%
Apr 17, 2024
Sandy Cove Advisors, LLC
unchanged
-
-86,798
1,218,360
0.56%
Apr 17, 2024
Slow Capital, Inc.
added
6.83
-13,253
4,820,530
0.77%
Apr 17, 2024
Kathleen S. Wright Associates Inc.
unchanged
-
-2,460
34,530
0.02%
Apr 16, 2024
Capital Asset Advisory Services LLC
unchanged
-
-12,987
243,206
0.01%
Apr 16, 2024
Arlington Trust Co LLC
sold off
-100
-3,995
-
-%
Apr 16, 2024
KRS Capital Management, LLC
reduced
-17.38
-63,290
213,395
0.17%
Apr 16, 2024
Register Financial Advisors LLC
reduced
-7.32
-29,978
192,332
0.10%
Apr 16, 2024
Cedar Mountain Advisors, LLC
unchanged
-
-1,968
27,624
0.01%

1–10 of 49

Are Funds Buying or Selling EXAS?

Are funds buying EXAS calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own EXAS
No. of Funds

Unveiling Exact Sciences Corp's Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 13, 2024
vanguard group inc
9.71%
17,559,751
SC 13G/A
Feb 09, 2024
wellington management group llp
5.83%
10,536,759
SC 13G/A
Jan 29, 2024
blackrock inc.
6.1%
11,103,191
SC 13G/A
Jan 23, 2024
jpmorgan chase & co
9.5%
17,342,002
SC 13G/A
Oct 10, 2023
jpmorgan chase & co
10.3%
18,652,296
SC 13G
Feb 10, 2023
ark investment management llc
9.03%
16,040,490
SC 13G/A
Feb 09, 2023
vanguard group inc
9.71%
17,252,465
SC 13G/A
Feb 07, 2023
blackrock inc.
6.4%
11,354,134
SC 13G/A
Feb 06, 2023
wellington management group llp
5.86%
10,404,476
SC 13G/A
Sep 12, 2022
price t rowe associates inc /md/
3.7%
6,464,337
SC 13G/A

Recent SEC filings of Exact Sciences Corp

View All Filings
Date Filed Form Type Document
Apr 17, 2024
8-K
Current Report
Apr 15, 2024
8-K
Current Report
Apr 03, 2024
4
Insider Trading
Apr 03, 2024
4
Insider Trading
Apr 02, 2024
144
Notice of Insider Sale Intent
Apr 01, 2024
144
Notice of Insider Sale Intent
Apr 01, 2024
4
Insider Trading
Mar 28, 2024
144
Notice of Insider Sale Intent
Mar 04, 2024
4
Insider Trading
Mar 04, 2024
4
Insider Trading

Peers (Alternatives to Exact Sciences Corp)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
174.9B
23.9B
-6.84% -7.21%
36.87
7.32
-10.33% -33.23%
39.7B
3.7B
-10.56% -2.00%
47
10.85
8.72% 24.44%
38.8B
6.7B
-10.14% -4.66%
31.4
5.76
-2.81% -6.58%
13.9B
9.3B
-2.39% -12.25%
16.33
1.51
-6.38% -9.73%
11.7B
4.1B
-14.60% 12.19%
24.62
2.83
3.86% -2.39%
11.5B
2.5B
2.50% -7.62%
-56.42
4.61
19.93% 67.26%
11.5B
1.9B
-4.08% 93.54%
40.69
6.1
29.17% 15.26%
10.5B
1.1B
-4.43% 64.16%
-24.22
9.73
31.99% 20.63%
MID-CAP
2.6B
929.2M
-20.98% -28.89%
1.7K
2.78
28.93% 111.61%
2.0B
563.9M
-7.02% -33.76%
-4.23
3.6
25.45% 26.76%
SMALL-CAP
417.9M
280.3M
-18.17% -10.74%
-2.2
1.49
-12.89% -148.37%
87.2M
31.2M
7.83% -86.85%
-0.99
2.79
5.03% -1.81%
43.6M
9.2M
-0.56% -37.52%
-2.61
4.76
11.85% 44.12%
5.8M
9.0M
-24.44% -66.67%
-0.8
0.64
-53.31% 2.21%
183.8K
25.9M
-50.00% -94.83%
-0.01
0.01
-57.78% -93.11%

Exact Sciences Corp News

Latest updates
Yahoo Movies UK12 hours ago
Seeking Alpha15 Apr 202410:19 am

Exact Sciences Corp Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
Income Statement (Quarterly)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q4
Revenue3.0%646,885,000628,338,000622,093,000602,450,000552,995,000523,073,000521,640,000486,571,000473,812,000456,379,000434,819,000402,077,000466,339,000408,363,000268,868,000347,821,000295,575,000218,805,000199,870,000162,043,000142,981,000
Cost Of Revenue2.0%171,865,000168,526,000156,991,000156,866,000147,152,000147,937,000144,600,000134,705,000119,058,000115,738,000113,968,000109,993,00099,765,00095,061,00077,892,00081,606,00070,416,00052,335,00051,139,00042,827,00037,827,000
Gross Profit------------------166,046,000148,307,000118,791,000104,821,000
Costs and Expenses4.0%721,126,000693,516,000699,022,000679,541,000671,877,000647,887,000681,224,000663,558,000695,262,000618,402,000606,483,000702,618,000881,318,000611,698,000359,542,000430,194,000391,655,000254,531,000233,772,000230,117,000-
Operating Expenses------------------201,706,000182,127,000186,985,000154,137,000
  S&GA Expenses10.0%190,477,000173,159,000176,490,000186,964,000210,211,000187,697,000215,922,000232,181,000284,304,000196,617,000194,827,000186,141,000166,827,000136,481,000118,862,000167,749,000119,851,00086,196,00088,190,00090,939,00076,773,000
  R&D Expenses3.1%114,922,000111,446,000104,095,00095,419,00094,274,00090,813,000106,083,000102,248,00088,488,00075,356,000106,235,000115,567,000446,447,00031,471,00032,673,00043,509,00043,223,00034,714,00029,972,00031,785,00020,700,000
EBITDA Margin52.8%-0.03-0.06-0.17-0.22-0.29-0.35-0.37-0.39-0.46-0.52-0.55-0.54---------
Interest Expenses494.2%31,029,000-7,871,000-7,818,0004,107,00033,858,000-5,235,000-4,511,000-4,478,00032,554,000-4,680,000-4,652,000-4,616,000131,323,000-4,478,000-4,300,000-54,604,000-13,688,000-13,209,000-12,712,000-21,990,000-10,972,000
Income Taxes-400.2%-600,500200,0001,107,0001,700,000-2,189,500-3,116,000-1,751,000-2,000,000-4,243,000-3,900,0004,000,000-242,800,000-164,000-2,752,000-305,000-2,237,000-184,628,000683,000-443,000-470,0007,000
Earnings Before Taxes-4929.9%-50,376,0001,043,000-79,919,000-72,494,000-129,927,000-151,877,000-167,814,000-182,952,000-224,854,000-170,796,000-172,887,000-273,969,000-418,496,000-205,290,000-68,397,000-136,880,000-106,683,000-39,842,000-38,945,000-83,409,000-53,967,000
EBT Margin31.0%-0.08-0.12-0.19-0.24-0.30-0.36-0.39-0.41-0.48-0.59-0.63-0.63---------
Net Income-6367.8%-49,766,000794,000-81,026,000-74,151,000-127,745,000-148,761,000-166,063,000-180,937,000-220,611,000-166,938,000-176,912,000-31,164,000-418,332,000-202,538,000-68,092,000-134,643,00077,973,000-40,525,000-38,502,000-82,939,000-53,974,000
Net Income Margin30.4%-0.08-0.12-0.19-0.23-0.30-0.36-0.38-0.40-0.34-0.45-0.48-0.47---------
Free Cashflow4292.1%34,627,000-826,00065,703,000-67,575,000-20,839,000-85,563,000-124,242,000-207,377,000-83,964,000-79,644,00015,753,000-90,147,000---------
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q4
Assets0.8%6,4716,4216,3566,3046,2276,3076,4376,4916,6856,6546,7246,7354,9254,3544,4684,4613,5061,7591,7821,7711,524
  Current Assets4.0%1,1941,1481,1741,0919821,0491,1021,2151,4261,6161,6691,7752,1991,6071,5051,4845541,3201,3751,4071,228
    Cash Equivalents1.8%6055956044212422352131903152743641,1041,4928077047011781,034205285160
  Inventory-4.0%12713313112411811511511310595.0090.0089.0092.0080.0082.0069.0062.0054.0048.0044.0039.00
  Net PPE-698---685--623580524502483452456463465455371335292245
  Goodwill0.0%2,3672,3672,3462,3462,3462,3452,3462,3352,3352,2432,24357.001,2381,2381,23830.001,203---15.00
Liabilities0.8%3,3263,3003,2993,2473,1843,1983,2283,2323,2973,1973,1653,0862,6902,0171,9571,9231,2181,0111,016994843
  Current Liabilities8.0%515477488367413424443481517710676629633253222244236481492168136
  Long Term Debt--------------1,5551,5341,51480447747025.0024.00
    LT Debt, Current-----------------1.003163120.000.00
    LT Debt, Non Current--------------1,5551,5341,51480447747025.0024.00
Shareholder's Equity0.8%3,1453,1213,0573,0583,0433,1093,2093,2583,3883,4583,5593,6492,2361,7311,8871,8961,958748766777447
  Retained Earnings-1.5%-3,469-3,419-3,420-3,339-3,265-3,137-2,988-2,822-2,641-2,420-2,253-2,077-2,045-1,531-1,311-1,225-1,119-1,197-1,157-1,118-1,035
  Additional Paid-In Capital1.1%6,6116,5406,4766,3976,3126,2556,2056,0866,0295,8775,8115,7244,2793,8663,8203,7633,4061,9451,9201,8941,717
Shares Outstanding0.3%181181181180178176176174171172170169---------
Float---16,796---6,905---21,212---12,901---15,070--
Cashflow (Last 12 Months)
(In Millions)
Cashflow (Quarterly)
(In Millions)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q4
Cashflow From Operations185.5%70.0024.00100-38.2252.00-40.93-60.92-173-24.57-40.7740.00-77.2311182.00-6.87-49.83-25.30-29.1517.00-74.15-0.85
  Share Based Compensation-5.3%59.0062.0062.0049.0046.0050.0059.0052.001135.001.0077.0042.0041.0040.0030.0048.0024.0020.0016.0016.00
Cashflow From Investing-102.5%-66.77-32.9766.0083.00-58.1665.0022.0046.0078.00-49.24-793-317-30617.00-6.38-405-838857-102-41.20-9.80
Cashflow From Financing10809.8%10.000.0016.0013410.000.0063.003.00-12.200.0013.007.008804.0016.009797.001.005.002409.00

EXAS Income Statement

2023-12-31
Consolidated Statements of Operations - USD ($)
shares in Thousands, $ in Thousands
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Income Statement [Abstract]   
Revenue$ 2,499,766$ 2,084,279$ 1,767,087
Operating expenses:   
Cost of sales (exclusive of amortization of acquired intangible assets)654,248574,394458,757
Research and development425,882393,418385,646
Sales and marketing727,090846,011861,889
General and administrative893,204737,304801,262
Amortization of acquired intangible assets92,16097,45095,001
Impairment of long-lived assets62115,96920,210
Total operating expenses2,793,2052,664,5462,622,765
Other operating income (loss)78,427(13,244)0
Loss from operations(215,012)(593,511)(855,678)
Other income (expense)   
Investment income (loss), net32,713(19,425)31,778
Interest expense(19,447)(19,634)(18,606)
Total other income (expense)13,266(39,059)13,172
Net loss before tax(201,746)(632,570)(842,506)
Income tax benefit (expense)(2,403)9,064246,881
Net loss$ (204,149)$ (623,506)$ (595,625)
Net loss per share - basic (in dollars per share)$ (1.13)$ (3.54)$ (3.48)
Net loss per share - diluted (in dollars per share)$ (1.13)$ (3.54)$ (3.48)
Weighted average common shares outstanding - basic (in shares)180,144176,351171,348
Weighted average common shares outstanding - diluted (in shares)180,144176,351171,348

EXAS Balance Sheet

2023-12-31
Consolidated Balance Sheets - USD ($)
$ in Thousands
Dec. 31, 2023
Dec. 31, 2022
Current assets:  
Cash and cash equivalents$ 605,378$ 242,493
Marketable securities172,266389,564
Accounts receivable, net203,623158,043
Inventory127,475118,259
Prepaid expenses and other current assets85,62773,898
Total current assets1,194,369982,257
Long-term assets:  
Property, plant and equipment, net698,354684,756
Operating lease right-of-use assets143,708167,003
Goodwill2,367,1202,346,040
Intangible assets, net1,890,3961,956,240
Other long-term assets, net177,38790,577
Total assets6,471,3346,226,873
Current liabilities:  
Accounts payable78,81674,916
Accrued liabilities341,683299,216
Operating lease liabilities, current portion29,37928,366
Other current liabilities14,82310,249
Total current liabilities514,701412,747
Convertible notes, net2,314,2762,186,106
Long-term debt, less current portion050,000
Other long-term liabilities335,982352,459
Operating lease liabilities, less current portion161,070182,399
Total liabilities3,326,0293,183,711
3326029000
Stockholders’ equity:  
Preferred stock, $0.01 par value Authorized—5,000,000 shares issued and outstanding—no shares at December 31, 2023 and December 31, 202200
Common stock, $0.01 par value Authorized—400,000,000 shares issued and outstanding—181,364,180 and 177,925,631 shares at December 31, 2023 and December 31, 20221,8151,780
Additional paid-in capital6,611,2376,311,644
Accumulated other comprehensive income (loss)1,428(5,236)
Accumulated deficit(3,469,175)(3,265,026)
Total stockholders’ equity3,145,3053,043,162
Total liabilities and stockholders’ equity6,471,3346,226,873
Loans Payable, Current$ 50,000$ 0
EXAS
Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services. The company's pipeline products focus on enhancing the Cologuard test's performance characteristics and developing blood and other fluid-based tests. It has license agreements with MAYO Foundation for Medical Education and Research; and Hologic, Inc. Exact Sciences Corporation was incorporated in 1995 and is headquartered in Madison, Wisconsin.
 CEO
 WEBSITEexactsciences.com
 INDUSTRYDiagnostics & Research
 EMPLOYEES6300

Exact Sciences Corp Frequently Asked Questions


What is the ticker symbol for Exact Sciences Corp? What does EXAS stand for in stocks?

EXAS is the stock ticker symbol of Exact Sciences Corp. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Exact Sciences Corp (EXAS)?

As of Thu Apr 18 2024, market cap of Exact Sciences Corp is 11.52 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of EXAS stock?

You can check EXAS's fair value in chart for subscribers.

What is the fair value of EXAS stock?

You can check EXAS's fair value in chart for subscribers. The fair value of Exact Sciences Corp is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Exact Sciences Corp is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for EXAS so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Exact Sciences Corp a good stock to buy?

The fair value guage provides a quick view whether EXAS is over valued or under valued. Whether Exact Sciences Corp is cheap or expensive depends on the assumptions which impact Exact Sciences Corp's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for EXAS.

What is Exact Sciences Corp's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Thu Apr 18 2024, EXAS's PE ratio (Price to Earnings) is -56.42 and Price to Sales (PS) ratio is 4.61. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. EXAS PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Exact Sciences Corp's stock?

In the past 10 years, Exact Sciences Corp has provided 0.174 (multiply by 100 for percentage) rate of return.